<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="publisher-id">IJEM</journal-id><journal-title-group><journal-title>Indian Journal of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2230-8210</issn><issn pub-type="epub">2230-9500</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24404506</article-id><article-id pub-id-type="pmc">3872914</article-id><article-id pub-id-type="publisher-id">IJEM-17-569</article-id><article-id pub-id-type="doi">10.4103/2230-8210.122139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Tamil Nadu cohort of the A<sub>1</sub>chieve study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shunmugavelu</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Giri</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Akhtar</surname><given-names>Shahid</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Shetty</surname><given-names>Raman</given-names></name><xref ref-type="aff" rid="aff3">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Asirvatham</surname><given-names>A. J.</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib></contrib-group><aff id="aff1"><italic>Trichy Diabetes Speciality Centre, Trichy, India</italic></aff><aff id="aff2"><label>1</label><italic>K.G Hospital and Post Graduate Medical Institute, Coimbatore, India</italic></aff><aff id="aff3"><label>2</label><italic>Novo Nordisk India Pvt. Ltd., Bangalore, India</italic></aff><aff id="aff4"><label>3</label><italic>Department of Diabetology, Madurai Medical College, Madurai, Tamil Nadu, India</italic></aff><author-notes><corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Raman Shetty, Novo Nordisk India Pvt. Ltd., Plot No.32, 47 - 50, EPIP Area, Whitefield, Bangalore, India. E-mail: <email xlink:href="rasy@novonordisk.com">rasy@novonordisk.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2013</year></pub-date><volume>17</volume><issue>Suppl 2</issue><fpage>S569</fpage><lpage>S573</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Endocrinology and Metabolism</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The A<sub>1</sub>chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (<italic>n</italic> = 66,726) in routine clinical care across four continents.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Tamil Nadu, India.</p></sec><sec id="st3"><title>Results:</title><p>A total of 2221 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (<italic>n</italic> = 1707), insulin detemir (<italic>n</italic> = 270), insulin aspart (<italic>n</italic> = 85), basal insulin plus insulin aspart (<italic>n</italic> = 79) and other insulin combinations (<italic>n</italic> = 80). At baseline glycaemic control was poor for both insulin na&#x000ef;ve (mean HbA<sub>1</sub>c: 9.2%) and insulin user (mean HbA<sub>1</sub>c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA<sub>1</sub>c (insulin na&#x000ef;ve: &#x02212;1.7%, insulin users: &#x02212;1.7%). SADRs including major hypoglycaemic events did not occur in any of the study patients.</p></sec><sec id="st4"><title>Conclusion:</title><p>Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.</p></sec></abstract><kwd-group><kwd>A<sub>1</sub>chieve study</kwd><kwd>insulin analogues</kwd><kwd>Tamil Nadu</kwd><kwd>type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>62.4 million Indians were reported to have type 2 diabetes mellitus (T2DM) putting India on the forefront of diabetic epidemic across globe.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref>] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.[<xref ref-type="bibr" rid="ref3">3</xref>] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.[<xref ref-type="bibr" rid="ref4">4</xref>] A<sub>1</sub>chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (<italic>n</italic> = 66,726) in routine clinical care.[<xref ref-type="bibr" rid="ref5">5</xref>] This short communication presents the results for patients enrolled from Tamil Nadu, India.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>M<sc>ATERIALS AND</sc> M<sc>ETHODS</sc></title><p>Please refer to editorial titled: The A1chieve study: Mapping the Ibn Battuta trail.</p></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><p>A total of 2221 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-na&#x000ef;ve and insulin users is shown in the <xref ref-type="table" rid="T1">Table 1</xref>. Glycaemic control at baseline was poor in this population. The majority of patients (76.86%) started on or were switched to biphasic insulin aspart. Other groups were insulin detemir (<italic>n</italic> = 270), insulin aspart (<italic>n</italic> = 85), basal insulin plus insulin aspart (<italic>n</italic> = 79) and other insulin combinations (<italic>n</italic> = 80).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Overall demographic data</p></caption><graphic xlink:href="IJEM-17-569-g001"/></table-wrap><p>After 24 weeks of treatment, overall hypoglycaemia reduced from 1.1 events/patient-year to 0.6 events/patient-year in insulin na&#x000ef;ve group and from 3.9 events/patient-year to 2.0 events/patient-year in insulin users group. The hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. Blood pressure decreased from baseline, while overall lipid profile and quality of life improved at week 24 in total cohort [Table <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Overall safety data</p></caption><graphic xlink:href="IJEM-17-569-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Insulin dose</p></caption><graphic xlink:href="IJEM-17-569-g003"/></table-wrap><p>All parameters of glycaemic control improved from baseline to study end in the total cohort [<xref ref-type="table" rid="T4">Table 4</xref>].</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Overall efficacy data</p></caption><graphic xlink:href="IJEM-17-569-g004"/></table-wrap><sec id="sec2-1"><title>Biphasic insulin aspart &#x000b1; OGLD</title><p>Of the total cohort, 1707 patients started on biphasic insulin aspart &#x000b1; OGLD, of which 1314 (77.0%) were insulin na&#x000ef;ve and 393 (23.0%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 0.9 events/patient-year to 0.6 events/patient-year in insulin na&#x000ef;ve group and from 3.4 events/patient-year to 1.8 events/patient-year in insulin users. Quality of life improved at the end of the study [Table <xref ref-type="table" rid="T5">5</xref> and <xref ref-type="table" rid="T6">6</xref>].</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Biphasic insulin aspart&#x000b1;oral glucose-lowering drug safety data</p></caption><graphic xlink:href="IJEM-17-569-g005"/></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Insulin dose</p></caption><graphic xlink:href="IJEM-17-569-g006"/></table-wrap><p>All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin na&#x000ef;ve and insulin user group [<xref ref-type="table" rid="T7">Table 7</xref>].</p><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Biphasic insulin aspart&#x000b1;oral glucose-lowering drug efficacy data</p></caption><graphic xlink:href="IJEM-17-569-g007"/></table-wrap></sec><sec id="sec2-2"><title>Basal + insulin aspart &#x000b1; OGLD</title><p>Of the total cohort, 79 patients who started on basal + insulin aspart &#x000b1; OGLD, of which 35 (44.3%) were insulin na&#x000ef;ve and 44 (55.7%) were insulin users. After 24 weeks of starting or switching to insulin aspart, hypoglycaemic events reduced from 2.2 events/patient-year to 0.8 events/patient-year in insulin na&#x000ef;ve group and from 6.5 events/patient-year to 1.7 events/patient-year in insulin users. Quality of life improved after 24 weeks of treatment [Table <xref ref-type="table" rid="T8">8</xref> and <xref ref-type="table" rid="T9">9</xref>].</p><table-wrap id="T8" position="float"><label>Table 8</label><caption><p>Basal+insulin aspart&#x000b1;oral glucose-lowering drug safety data</p></caption><graphic xlink:href="IJEM-17-569-g008"/></table-wrap><table-wrap id="T9" position="float"><label>Table 9</label><caption><p>Insulin dose</p></caption><graphic xlink:href="IJEM-17-569-g009"/></table-wrap><p>All parameters of glycaemic control improved from baseline to study end in those who started on or switched to basal + insulin aspart &#x000b1; OGLDs for both insulin na&#x000ef;ve and insulin user groups [<xref ref-type="table" rid="T10">Table 10</xref>].</p><table-wrap id="T10" position="float"><label>Table 10</label><caption><p>Basal+insulin aspart&#x000b1;oral glucose-lowering drug efficacy data</p></caption><graphic xlink:href="IJEM-17-569-g010"/></table-wrap></sec><sec id="sec2-3"><title>Insulin detemir &#x000b1; OGLD</title><p>On the total cohort, 270 patients who started on insulin detemir &#x000b1; OGLD, of which 224 (83.0%) were insulin na&#x000ef;ve and 46 (17.0%) were insulin users. After 24 weeks of starting or switching to biphasic insulin detemir, hypoglycaemic events reduced from 2.2 events/patient-year to 0.7 events/patient-year in insulin na&#x000ef;ve group and from 4.8 events/patient-year to 2.1 events/patient-year in insulin users group. A small increase in body weight was observed. Quality of life improved at 24 weeks [Table <xref ref-type="table" rid="T11">11</xref> and <xref ref-type="table" rid="T12">12</xref>].</p><table-wrap id="T11" position="float"><label>Table 11</label><caption><p>Insulin detemir&#x000b1;oral glucose-lowering drug safety data</p></caption><graphic xlink:href="IJEM-17-569-g011"/></table-wrap><table-wrap id="T12" position="float"><label>Table 12</label><caption><p>Insulin dose</p></caption><graphic xlink:href="IJEM-17-569-g012"/></table-wrap><p>All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir &#x000b1; OGLDs for both insulin-na&#x000ef;ve and insulin user groups [<xref ref-type="table" rid="T13">Table 13</xref>].</p><table-wrap id="T13" position="float"><label>Table 13</label><caption><p>Insulin detemir&#x000b1;oral glucose-lowering drug efficacy data</p></caption><graphic xlink:href="IJEM-17-569-g013"/></table-wrap></sec><sec id="sec2-4"><title>Insulin aspart &#x000b1; OGLD</title><p>Of the total cohort, 85 patients who started on insulin aspart &#x000b1; OGLD, of which 69 (81.2%) were insulin na&#x000ef;ve and 16 (18.8%) were insulin users. After 24 weeks of treatment starting or switching to insulin aspart hypoglycaemic events reduced from 15.4 events/patient-year to 5.2 events/patient-year in insulin users group, while hypoglycaemia increased from 0.0 events/patient-year to 0.2 events/patient-year in insulin na&#x000ef;ve group. An improvement in quality of life was observed after 24 weeks [Table <xref ref-type="table" rid="T14">14</xref> and <xref ref-type="table" rid="T15">15</xref>].</p><table-wrap id="T14" position="float"><label>Table 14</label><caption><p>Insulin aspart&#x000b1;oral glucose-lowering drug safety data</p></caption><graphic xlink:href="IJEM-17-569-g014"/></table-wrap><table-wrap id="T15" position="float"><label>Table 15</label><caption><p>Insulin dose</p></caption><graphic xlink:href="IJEM-17-569-g015"/></table-wrap><p>All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart &#x000b1; OGLDs for both insulin na&#x000ef;ve and insulin user groups [<xref ref-type="table" rid="T16">Table 16</xref>].</p><table-wrap id="T16" position="float"><label>Table 16</label><caption><p>Insulin aspart&#x000b1;oral glucose-lowering drug efficacy data</p></caption><graphic xlink:href="IJEM-17-569-g016"/></table-wrap></sec></sec><sec sec-type="conclusion" id="sec1-4"><title>C<sc>ONCLUSION</sc></title><p>Our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues (biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. A slight increase in body weight was observed for the total cohort. SADRs including major hypoglycaemic events did not occur in any of the study patients. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Tamil Nadu, India.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Sicree</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>H</given-names></name></person-group><article-title>Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1047</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15111519</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>P</given-names></name></person-group><article-title>Public health: India's diabetes time bomb</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>S14</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22616100</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korytkowski</surname><given-names>M</given-names></name></person-group><article-title>When oral agents fail: Practical barriers to starting insulin</article-title><source>Int J Obes Relat Metab Disord</source><year>2002</year><volume>26</volume><issue>Suppl 3</issue><fpage>S18</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12174319</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>IB</given-names></name></person-group><article-title>Insulin analogues</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>174</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15647580</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>SN</given-names></name><name><surname>Litwak</surname><given-names>L</given-names></name><name><surname>Haddad</surname><given-names>J</given-names></name><name><surname>Chakkarwar</surname><given-names>PN</given-names></name><name><surname>Hajjaji</surname><given-names>I</given-names></name></person-group><article-title>The A 1 chieve study: A 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice</article-title><source>Diabetes Res Clin Pract</source><year>2010</year><volume>88</volume><issue>Suppl 1</issue><fpage>S11</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20466163</pub-id></element-citation></ref></ref-list></back></article>